title: Carbapenems: the pinnacle of the beta-lactam antibiotics or room for improvement?
authors.affiliation: Cancer and Infection Research Department, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK. Jeff.Edwards@astrazeneca.com
authors.forename: J R
authors.initials: JR
authors.lastname: Edwards
authors.forename: M J
authors.initials: MJ
authors.lastname: Betts
mesh_terms: D000150:Acinetobacter / Q000187:drug effects; D000818:Animals; D001424:Bacterial Infections / Q000188:drug therapy; D015780:Carbapenems / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004352:Drug Resistance, Microbial; D004355:Drug Stability; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests; D011550:Pseudomonas aeruginosa / Q000187:drug effects*
chemical_list: D015780:Carbapenems